Abrocitinib 200mg Tablets — JAK1 Inhibitor for Moderate to Severe Atopic Dermatitis
Cibinqo® (Abrocitinib) — Targeted JAK1 Inhibitor for Atopic Dermatitis
A Sourcing Guide for Hospitals, Dermatology Clinics, and Pharmacies
Cibinqo® (Abrocitinib) is a selective Janus kinase 1 (JAK1) inhibitor indicated, according to the manufacturer’s approved prescribing information, for the treatment of adults and adolescents with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic therapies, including biologics, or when the use of those therapies is inadvisable. As with all systemic dermatology therapies, the decision to prescribe Cibinqo rests entirely with the treating dermatologist, in accordance with the approved label. This page provides sourcing and procurement information for hospitals, clinics, and pharmacies, not clinical or treatment guidance.
As both a trusted medicine distributor in Delhi and a licensed pharmaceutical distributor in Delhi, A.K. Pharma supplies genuine Cibinqo (Abrocitinib) 200mg to hospitals, dermatology clinics, and pharmacies across India.
Cibinqo contains Abrocitinib, an oral small-molecule inhibitor that selectively targets Janus kinase 1 (JAK1), one of four members of the JAK family of intracellular enzymes involved in cytokine signalling.
The JAK-STAT Pathway and Its Role in Atopic Dermatitis:
According to published dermatology and immunology literature, atopic dermatitis is driven substantially by a group of cytokines — including interleukin-4 (IL-4), interleukin-13 (IL-13), interleukin-31 (IL-31), and thymic stromal lymphopoietin (TSLP) — that signal through receptors dependent on JAK1 activity. When these cytokines bind their receptors, JAK1 phosphorylates STAT proteins, which then translocate to the cell nucleus and drive transcription of genes associated with skin inflammation, barrier disruption, and the intense itch characteristic of atopic dermatitis.
Abrocitinib’s Mechanism: By selectively inhibiting JAK1, Abrocitinib interrupts signalling from this specific group of cytokines implicated in atopic dermatitis pathophysiology, according to the manufacturer’s prescribing information. Its selectivity for JAK1 over JAK2, JAK3, and TYK2 is designed to concentrate its effect on the pathways most relevant to atopic dermatitis while limiting activity on unrelated JAK-dependent processes, such as those involved in blood cell production.
Full prescribing information is available at the FDA label for Abrocitinib.
JADE MONO-1 and JADE MONO-2 Trials (Abrocitinib Monotherapy)
Published in JAMA Dermatology (2020) and the Lancet (2020) respectively, these Phase 3 trials evaluated Abrocitinib monotherapy in adolescents and adults with moderate to severe atopic dermatitis. Both trials demonstrated significantly higher rates of clear or almost clear skin (IGA response) and improvement in itch compared to placebo at Week 12.
JADE COMPARE Trial (Abrocitinib vs Dupilumab, Both With Topical Therapy)
Published in the New England Journal of Medicine (2021), JADE COMPARE compared Abrocitinib 200mg, Abrocitinib 100mg, and Dupilumab, all combined with background topical therapy, against placebo. Key findings included significantly greater itch response as early as Week 2 with Abrocitinib 200mg compared to Dupilumab, alongside comparable overall skin clearance outcomes, providing head-to-head comparative data between the two treatment classes.
JADE REGIMEN Trial (Long-Term Maintenance)
Published in the British Journal of Dermatology (2022), JADE REGIMEN evaluated flare prevention with continued Abrocitinib therapy in patients who had achieved initial treatment response, supporting its role in long-term disease maintenance.
Cibinqo is available as:
| Presentation | Strength |
|---|---|
| Cibinqo 200mg Tablets | 200mg per tablet |
Cibinqo is also available in lower strengths per the manufacturer’s full product range; dosing selection is determined by the prescribing dermatologist based on patient-specific factors, in accordance with the approved label.
Refractory Moderate to Severe Atopic Dermatitis:
For detailed indication information refer to MedlinePlus Abrocitinib.
Oral Administration
Unlike biologic therapies for atopic dermatitis that require injection, Cibinqo is administered as an oral tablet, which may be a relevant consideration for patients and prescribers weighing treatment options.
Rapid Itch Response Demonstrated in Trials
JADE COMPARE demonstrated significantly greater itch improvement as early as Week 2 with Abrocitinib 200mg compared to Dupilumab, addressing one of the most burdensome symptoms of atopic dermatitis for patients.
Option for Patients With Inadequate Response to Biologics
For patients whose atopic dermatitis remains inadequately controlled on biologic therapy, or where biologics are not suitable, Cibinqo provides an alternative systemic treatment mechanism targeting the JAK1 pathway.
Long-Term Maintenance Data
JADE REGIMEN trial data supports continued use for flare prevention in patients who have achieved initial response, relevant for long-term disease management planning.
Dosing of Cibinqo is determined by the prescribing dermatologist according to the approved label. General administration information from the manufacturer’s prescribing information includes:
Monitoring (per manufacturer prescribing information):
Full dosing guidelines are available in the manufacturer’s official prescribing information and should always be followed exactly as directed by the treating dermatologist.
Cibinqo is prescribed by dermatologists for:
Cibinqo is prescribed by dermatologists specialising in atopic dermatitis and other inflammatory skin conditions. A.K. Pharma supplies Cibinqo to hospitals, dermatology clinics, and pharmacies across Delhi and India.
Common side effects reported in clinical trials include nausea, headache, and acne.
Serious side effects include:
Serious Infections: JAK inhibitors as a class carry a Boxed Warning regarding serious infections, including tuberculosis and opportunistic infections; screening prior to initiation and monitoring throughout treatment is recommended per the approved label.
Malignancy: A Boxed Warning addresses the observed risk of malignancy, including lymphoma, associated with the JAK inhibitor class, based on data from this therapeutic class.
Major Adverse Cardiovascular Events (MACE): A Boxed Warning addresses cardiovascular risk observed with the JAK inhibitor class, relevant particularly in patients with existing cardiovascular risk factors.
Thrombosis: A Boxed Warning addresses the risk of venous thromboembolism and arterial thrombosis associated with this therapeutic class.
Cytopenias: Reductions in blood cell counts have been reported; complete blood count monitoring is recommended per the approved prescribing information.
Full side effect information is available at FDA Abrocitinib Safety Information.
As a responsible medicine distributor in Delhi, A.K. Pharma stores all dermatology medicines including Cibinqo under manufacturer-recommended conditions ensuring product integrity for every supply.
Cibinqo (Abrocitinib) is manufactured by Pfizer. Abrocitinib received regulatory approval for moderate to severe atopic dermatitis in patients not adequately controlled with other systemic therapies. A.K. Pharma supplies only genuine Cibinqo sourced from authorised distributors.
Q. What is Cibinqo used for?
Cibinqo (Abrocitinib) is used to treat refractory, moderate to severe atopic dermatitis in adults and adolescents not adequately controlled with other systemic therapies, including biologics, or where those therapies are not suitable.
Q. What is the generic name of Cibinqo?
The generic name of Cibinqo is Abrocitinib, a selective JAK1 inhibitor.
Q. How is Cibinqo different from Dupixent for atopic dermatitis?
Cibinqo is an oral JAK1 inhibitor, while Dupixent (Dupilumab) is an injectable biologic targeting IL-4 and IL-13 signalling. The JADE COMPARE trial found Cibinqo 200mg demonstrated faster itch improvement in the trial period compared to Dupilumab, though treatment selection depends on individual patient factors determined by the treating dermatologist.
Q. Why does Cibinqo carry Boxed Warnings?
As a member of the JAK inhibitor class, Cibinqo carries Boxed Warnings for serious infections, malignancy, major cardiovascular events, and thrombosis, consistent with warnings applied across this therapeutic class based on clinical trial and post-marketing data.
Q. Is Cibinqo available in India?
Cibinqo can be supplied to hospitals, dermatology clinics, and pharmacies across India through licensed pharmaceutical distributors. Contact A.K. Pharma — medicine distributor in Delhi and pharmaceutical distributor in Delhi — for availability and pricing.
Q. What is the price of Cibinqo in India?
Cibinqo price in India varies by pack size and strength. Contact A.K. Pharma at 011 4172 6999 or WhatsApp +91 9810034827 for current pricing and bulk supply rates.
Q. How to order Cibinqo from A.K. Pharma?
You can request a quote directly from this page, call us at 011 4172 6999, or WhatsApp us at +91 9810034827 with your requirements and we will respond promptly.
Q. Does A.K. Pharma supply Cibinqo in bulk?
Yes. A.K. Pharma supplies Cibinqo in bulk to hospitals, dermatology clinics, and pharmacies across Delhi and India.
📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052
📞 011 4172 6999
📱 WhatsApp: +91 9810034827
🌐 akpharma.in
Disclaimer: This page is intended for informational and sourcing/procurement purposes only and does not constitute medical or clinical advice. All treatment decisions, including drug selection and dosing, should be made by a qualified healthcare professional in accordance with the approved prescribing information. A.K. Pharma is a licensed medicine distributor and does not provide clinical guidance.
